Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its second pre-planned data review meeting and recommended the continuation of the Company’s trial without protocol amendment. This second review was based on data collected from 77 randomized patients including at least 60 patients who have completed their week 6 visit. The Company expects interim efficacy results in Fall 2018 and final results in the first half of 2019.
More information on :

 

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2018/Genkyotex_PR_Second_IRB_Meeting_ENG_20180903.pdf